^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TT11

    i
    Other names: TT11, CD30.CAR-T cell therapy, TT11 CD30 CAR Ts, CD30.CAR-T, ATLCAR.CD30 cell therapy, ATLCAR.CD30 cells, CAR.CD30 T cell therapy, TT-11, TT 11
    Company:
    Baylor Scott & White Research Institute, Tessa Therap, UNC Lineberger Comprehensive Cancer Center
    Drug class:
    CD30-targeted CAR-T immunotherapy
    Related drugs:
    9d
    CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) (clinicaltrials.gov)
    P1, N=60, Recruiting, Baylor College of Medicine | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive
    |
    cyclophosphamide • TT11
    5ms
    CD30 CAR for CD30+ NSGCT (clinicaltrials.gov)
    P2, N=2, Completed, UNC Lineberger Comprehensive Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2030 --> Dec 2025
    Trial completion • Trial completion date
    |
    cyclophosphamide • fludarabine IV • TT11
    6ms
    LCCC 1606-ATL: Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL (clinicaltrials.gov)
    P1, N=43, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Sep 2041 --> Nov 2039 | Trial primary completion date: Sep 2026 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • CCR4 (C-C Motif Chemokine Receptor 4)
    |
    TNFRSF8 positive • TNFRSF8 expression
    |
    bendamustine • fludarabine IV • TT11 • ATLCAR.CD30.CCR4 cells
    7ms
    Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL (clinicaltrials.gov)
    P1/2, N=38, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Aug 2038 --> Nov 2039 | Trial primary completion date: Sep 2027 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    TT11
    7ms
    CD30 CAR for CD30+ NSGCT (clinicaltrials.gov)
    P2, N=2, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=18 --> 2 | Trial completion date: Aug 2030 --> Dec 2030 | Trial primary completion date: Sep 2026 --> Dec 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • TT11
    8ms
    CD30 CAR for CD30+ NSGCT (clinicaltrials.gov)
    P2, N=18, Recruiting, UNC Lineberger Comprehensive Cancer Center | Active, not recruiting --> Recruiting | Trial primary completion date: Sep 2025 --> Sep 2026
    Enrollment open • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • TT11
    11ms
    CD30 CAR for CD30+ NSGCT (clinicaltrials.gov)
    P2, N=18, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Dec 2026 --> Aug 2030 | Trial primary completion date: Dec 2026 --> Sep 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • TT11
    over1year
    Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL (clinicaltrials.gov)
    P1/2, N=40, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Aug 2040 --> Aug 2038 | Trial primary completion date: Aug 2025 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    TT11
    almost2years
    ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells (clinicaltrials.gov)
    P1/2, N=31, Recruiting, UNC Lineberger Comprehensive Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker
    |
    TT11 • ATLCAR.CD30.CCR4 cells
    over2years
    CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma (clinicaltrials.gov)
    P2, N=20, Recruiting, UNC Lineberger Comprehensive Cancer Center
    Trial completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    cyclophosphamide • fludarabine IV • TT11
    over2years
    Administration of T Lymphocytes for Prevention of Relapse of Lymphomas (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center
    Trial completion date
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression • ALK negative • TNFRSF8 negative
    |
    TT11
    almost3years
    Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL (clinicaltrials.gov)
    P1/2, N=40, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Aug 2038 --> Aug 2040 | Trial primary completion date: Aug 2023 --> Aug 2025
    Trial completion date • Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    TT11